Over the past 40 years, the safety and efficacy of percutaneous coronary intervention has dramatically improved by overcoming several challenges. The introduction of drug-eluting stent (DES) in particular was a major breakthrough in interventional cardiology. Compared to bare-metal stents, first-generation DES (G1-DES) has dramatically reduced the rates of in-stent restenosis and subsequent target lesion revascularization. However, major safety concerns surrounding stent thrombosis (ST) emerged with G1-DES in clinical practice as a result of the high incidences of death, myocardial infarction, and repeat revascularization associated with ST. To overcome these limitations, second-generation DES (G2-DES) has been developed with an improved stent platform with thinner strut and biocompatible durable or biodegradable polymers. Indeed, G2-DES, when compared with G1-DES, has improved clinical outcomes by reducing the risk of late thrombotic events while maintaining anti-restenotic efficacy, whereas ST still occurs, even with the use of G2-DES. This review gives an overview of pathophysiology, risk factors, and outcomes of ST after DES implantation. Additionally, we discuss the management and prevention of ST.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.
van Werkum JW, Heestermans AA, de Korte FI, Kelder JC, Suttorp MJ, Rensing BJ, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation. 2009;119:828–34.
Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010;122:52–61.
Kuramitsu S, Matsuda H, Jinnouchi H, Yamaji K, Hiromasa T, Matsumura Y, et al. Long-term (7 to 10 years) clinical outcomes after first-generation sirolimus-eluting stent implantation. Asia Interv. 2016;2:93–100.
Galløe AM, Kelbæk H, Thuesen L, Hansen HS, Ravkilde J, Hansen PR, et al. 10-year clinical outcome after randomization to treatment by sirolimus- or paclitaxel-eluting coronary stents. J Am Coll Cardiol. 2017;69:616–24.
Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6:1267–74.
Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Valgimigli M, et al. Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2013;62:496–504.
Philip F, Agarwal S, Bunte MC, Goel SS, Tuzcu EM, Ellis S, Kapadia SR. Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: network meta-analysis of primary percutaneous coronary intervention trials in ST-segment–elevation myocardial infarction [corrected]. Circ Cardiovasc Interv. 2014;7:49–61.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.
Holmes DR Jr, Kereiakes DJ, Garg S, Serruys PW, Dehmer GJ, Ellis SG, et al. Stent thrombosis. J Am Coll Cardiol. 2010;56:1357–65.
Claessen BE, Henriques JP, Jaffer FA, Mehran R, Piek JJ, Dangas GD. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv. 2014;7:1081–92.
Torrado J, Buckley L, Durán A, Trujillo P, Toldo S, Valle JR, et al. Restenosis, stent thrombosis, and bleeding complications: navigating between scylla and charybdis. J Am Coll Cardiol. 2018;71:1676–95.
Kuramitsu S, Iwabuchi M, Haraguchi T, Domei T, Nagae A, Hyodo M, et al. Incidence and clinical impact of stent fracture after everolimus-eluting stent implantation. Circ Cardiovasc Interv. 2012;5:663–71.
Kuramitsu S, Ohya M, Shinozaki T, Otake H, Horie K, Kawamoto H, et al. Risk factors and long-term clinical outcomes of second-generation drug-eluting stent thrombosis: insights from the REAL-ST registry. Circ Cardiovasc Interv. 2019;12:e007822.
Cayla G, Hulot JS, O’Connor SA, Pathak A, Scott SA, Gruel Y, et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011;306:1765–74.
Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation. 2012;125:584–91.
Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol. 2005;45:995–8.
Choi SY, Witzenbichler B, Maehara A, Lansky AJ, Guagliumi G, Brodie B, et al. Intravascular ultrasound findings of early stent thrombosis after primary percutaneous intervention in acute myocardial infarction: a Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) substudy. Circ Cardiovasc Interv. 2011;4:239–47.
D’Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, et al. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013;167:575–84.
Sarno G, Lagerqvist B, Nilsson J, Frobert O, Hambraeus K, Varenhorst C, et al. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. J Am Coll Cardiol. 2014;64:16–24.
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–30.
van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol. 2009;53:1399–409.
Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30:2714–21.
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet. 2013;382:1714–22.
Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614–23.
Kuramitsu S, Jinnouchi H, Shinozaki T, Hiromasa T, Matsumura Y, Yamaji Y, et al. Incidence and long-term clinical impact of late-acquired stent fracture after sirolimus-eluting stent implantation in narrowed coronary arteries. Am J Cardiol. 2017;120:55–62.
Nakamura M, Kadota K, Takahashi A, Kanda J, Anzai H, Ishii Y, et al. Relationship between platelet reactivity and ischemic and bleeding events after percutaneous coronary intervention in East Asian patients: 1-year results of the PENDULUM Registry. J Am Heart Assoc. 2020;9:e015439.
Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011;123:2382–91.
Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.
Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435–41.
Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299–307.
Palmerini T, Benedetto U, Biondi-Zoccai G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2015;65:2496–507.
Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129:211–23.
Jinnouchi H, Kuramitsu S, Shinozaki T, Kobayashi Y, Hiromasa T, Morinaga T, et al. Two-year clinical outcomes of newer-generation drug-eluting stent implantation following rotational atherectomy for heavily calcified lesions. Circ J. 2015;79:1938–43.
Nishida K, Nakatsuma K, Shiomi H, Natsuaki M, Kawai K, Morimoto T, et al. Second-generation vs. first-generation drug-eluting stents in patients with calcified coronary lesions- pooled analysis from the RESET and NEXT trials. Circ J. 2018;82:376–87.
Morofuji T, Kuramitsu S, Shinozaki T, Jinnouchi H, Sonoda S, Domei T, et al. Clinical impact of calcified nodule in patients with heavily calcified lesions requiring rotational atherectomy. Catheter Cardiovasc Interv. 2020. https://doi.org/10.1002/ccd.28896.
Redfors B, Généreux P, Witzenbichler B, Maehara A, Weisz G, McAndrew T, Mehran R, Kirtane AJ, Stone GW. Percutaneous coronary intervention of lesions with in-stent restenosis: a report from the ADAPT-DES study. Am Heart J. 2018;197:142–9.
Adriaenssens T, Joner M, Godschalk TC, Malik N, Alfonso F, Xhepa E, et al. Optical coherence tomography findings in patients with coronary stent thrombosis: a report of the PRESTIGE Consortium (prevention of late stent thrombosis by an interdisciplinary global European effort). Circulation. 2017;136:1007–21.
Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–22.
Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol. 2012;59:2051–7.
Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36:2147–59.
Lee SY, Hur SH, Lee SG, Kim SW, Shin DH, Kim JS, et al. Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv. 2015;8:e001878.
Taniwaki M, Radu MD, Zaugg S, Amabile N, Garcia-Garcia HM, Yamaji K, et al. Mechanisms of very late drug-eluting stent thrombosis assessed by optical coherence tomography. Circulation. 2016;133:650–60.
Kuroda M, Otake H, Shinke T, Takaya T, Nakagawa M, Osue T, et al. The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from the Kobe University Hospital optical coherence tomography registry. EuroIntervention. 2016;12:e1366–74.
Kuramitsu S, Sonoda S, Shinozaki T, Jinnouch H, Muraoka Y, Domei T, et al. Impact of lesion complexity on long-term vascular response to cobalt-chromium everolimus-eluting stent: five-year follow-up optical coherence tomography study. Heart Vessels. 2018;33:341–50.
Taniwaki M, Windecker S, Zaugg S, Stefanini GG, Baumgartner S, Zanchin T, et al. The association between in-stent neoatherosclerosis and native coronary artery disease progression: a long-term angiographic and optical coherence tomography cohort study. Eur Heart J. 2015;36:2167–76.
Jang JY, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, et al. Favorable effect of optimal lipid-lowering therapy on neointimal tissue characteristics after drug-eluting stent implantation: qualitative optical coherence tomographic analysis. Atherosclerosis. 2015;242:553–9.
Kuroda K, Otake H, Shinohara M, Kuroda M, Tsuda S, Toba T, et al. Effect of rosuvastatin and eicosapentaenoic acid on neoatherosclerosis: the LINK-IT Trial. EuroIntervention. 2019;15:e1099–106.
Iqbal J, Serruys PW, Silber S, Kelbaek H, Richardt G, Morel MA, et al. Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial. Circ Cardiovasc Interv. 2015;8:e002230.
Wijns W, Valdes-Chavarri M, Richardt G, Moreno R, Íñiguez-Romo A, Barbato E, et al. Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. EuroIntervention. 2018;14:e343–51.
Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, et al. Five-year outcome of a randomised trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: the NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent trial (NEXT). EuroIntervention. 2018;14:815–8.
Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Muller O, et al. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018;392:737–46.
Buiten RA, Ploumen EH, Zocca P, Doggen CJM, Danse PW, Schotborgh CE, et al. Thin, very thin, or ultrathin strut biodegradable or durable polymer-coated drug-eluting stents: 3-year outcomes of BIO-RESORT. JACC Cardiovasc Interv. 2019;12:1650–60.
Kandzari DE, Koolen JJ, Doros G, Garcia-Garcia HM, Bennett J, Roguin A, et al. Ultrathin bioresorbable-polymer sirolimus-eluting stents versus thin durable-polymer everolimus-eluting stents for coronary revascularization: 3-year outcomes from the randomized BIOFLOW V trial. JACC Cardiovasc Interv. 2020;13:1343–53.
Shiomi H, Kozuma K, Morimoto T, Kadota K, Tanabe K, Morino Y, et al. 7-Year outcomes of a randomized trial comparing the first-generation sirolimus-eluting stent versus the new-generation everolimus-eluting stent: the RESET trial. JACC Cardiovasc Interv. 2019;12:637–47.
Dangas GD, Claessen BE, Mehran R, Brener S, Brodie BR, Dudek D, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol. 2012;59:1752–9.
Mitsutake Y, Konishi A, Handa N, Ho M, Shirato H, Ito T, et al. Independent factors for in-hospital death following drug-eluting stent thrombosis from the japanese adverse event report system. Circ J. 2020;84:1568–74.
Horie K, Kuramitsu S, Shinozaki T, Ohya M, Otake H, Yamanaka F, et al. Outcomes after first- versus second-generation drug-eluting stent thrombosis (from the REAL-ST Registry). Am J Cardiol. 2020;132:52–8.
de la Torre-Hernández JM, Alfonso F, Hernández F, Elizaga J, Sanmartin M, Pinar E, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008;51:986–90.
Armstrong EJ, Yeo KK, Javed U, Mahmud E, Patel M, Shunk KA, et al. Angiographic stent thrombosis at coronary bifurcations: short- and long-term prognosis. JACC Cardiovasc Interv. 2012;5:57–63.
Katsikis A, Keeble TR, Davies JR, Jagathesan R, Kabir A, Sayer JW, et al. Contemporary management of stent thrombosis: Predictors of mortality and the role of new-generation drug-eluting stents. Catheter Cardiovasc Interv. 2020;96:E8–16.
Watanabe Y, Sakakura K, Fujita H, Ohya M, Horie K, Yamanaka F, et al. Comparison of clinical characteristics of stent thrombosis between the right coronary artery and the left coronary artery. A subanalysis of the REAL-ST registry. Circ J. 2020;84:169–77.
Chechi T, Vecchio S, Vittori G, Giuliani G, Lilli A, Spaziani G, et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol. 2008;51:2396–402.
Ohno Y, Yamaji K, Kohsaka S, Inohara T, Amano T, Ishii H, et al. Incidence and in-hospital outcomes of patients presenting with stent thrombosis (from the Japanese Nationwide Percutaneous Coronary Intervention Registry). Am J Cardiol. 2020;125:720–6.
Kim MC, Kim IS, Jeong MH, Sim DS, Hong YJ, Kim JH, et al. Incidence of cardiac death and recurrent stent thrombosis after treatment for angiographically confirmed stent thrombosis. J Cardiol. 2019;74:267–72.
Armstrong EJ, Sab S, Singh GD, Lim W, Yeo KK, Waldo SW, et al. Predictors and outcomes of recurrent stent thrombosis: results from a multicenter registry. JACC Cardiovasc Interv. 2014;7:1105–13.
Enomoto S, Kuramitsu S, Shinozaki T, Ohya M, Otake H, Yamanaka F, et al. Risk factors and outcomes of recurrent drug-eluting stent thrombosis: insights from the REAL-ST Registry. J Am Heart Assoc. 2021. https://doi.org/10.1161/JAHA.120.018972.
Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther. 2018;33:178–203.
Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. ESC/EACTS guidelines on myocardial revascularization. EuroIntervention. 2018;2019(14):1435–534.
Satoh S, Inoue H, Omura S, Ejima E, Shimozono K, Hayashi M, et al. Comparison of the reperfusion efficacy of thrombus aspiration with and without distal protection during primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol. 2013;112:1725–9.
Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, et al. Thrombus aspiration in ST-segment-elevation myocardial infarction: an individual patient meta-analysis: thrombectomy trialists collaboration. Circulation. 2017;135:143–52.
Sonoda S, Hibi K, Okura H, Fujii K, Honda Y, Kobayashi Y. Current clinical use of intravascular ultrasound imaging to guide percutaneous coronary interventions. Cardiovasc Interv Ther. 2020;35:30–6.
Biscaglia S, Tebaldi M, Tumscitz C, Pavasini R, Marchesini J, Gallo F, et al. Prospective identification of stent fracture by enhanced stent visualization system during percutaneous coronary intervention. Circ J. 2016;81:82–9.
Fanaroff AC, Kaltenbach LA, Peterson ED, Akhter MW, Effron MB, Henry TD, et al. Antiplatelet therapy changes for patients with myocardial infarction with recurrent ischemic events: insights into contemporary practice from the TRANSLATE-ACS (treatment with ADP receptor inhibitors: longitudinal assessment of treatment patterns and events after acute coronary syndrome) study. J Am Heart Assoc. 2018;7:e007982.
Sawayama Y, Yamamoto T, Tomita Y, Asada K, Yagi N, Fukuyama M, et al. Comparison between clopidogrel and prasugrel associated with CYP2C19 genotypes in patients receiving percutaneous coronary intervention in a Japanese population. Circ J. 2020;84:1575–81.
Stefanescu Schmidt AC, Kereiakes DJ, Cutlip DE, Yeh RW, D’Agostino RB Sr, et al. Myocardial infarction risk after discontinuation of thienopyridine therapy in the randomized DAPT study (dual antiplatelet therapy). Circulation. 2017;135:1720–32.
Witzenbichler B, Maehara A, Weisz G, Neumann FJ, Rinaldi MJ, Metzger DC, et al. Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. Circulation. 2014;129:463–70.
Choi KH, Song YB, Lee JM, Lee SY, Park TK, Yang JH, et al. Impact of intravascular ultrasound-guided percutaneous coronary intervention on long-term clinical outcomes in patients undergoing complex procedures. JACC Cardiovasc Interv. 2019;12:607–20.
Hong SJ, Mintz GS, Ahn CM, Kim JS, Kim BK, Ko YG, et al. Effect of intravascular ultrasound-guided drug-eluting stent implantation: 5-year follow-up of the IVUS-XPL randomized trial. JACC Cardiovasc Interv. 2020;13:62–71.
Moalem K, Baber U, Chandrasekhar J, Claessen BE, Sartori S, Aquino M, et al. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol. 2019;108:643–50.
Serruys PW, Kogame N, Katagiri Y, Modolo R, Buszman PE, Íñiguez-Romo A, et al. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: two-year follow-up of the SYNTAX II study. EuroIntervention. 2019;15:e244–52.
Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020;382:1395–407.
Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Piña IL, et al. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction: insights from the ISCHEMIA trial. Circulation. 2020;142:1725–35.
Conflict of interest
All authors have reported that they have no relationship relevant to the contents of this paper to disclose.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kuramitsu, S., Sonoda, S., Ando, K. et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv and Ther (2021). https://doi.org/10.1007/s12928-021-00754-x
- Stent thrombosis
- Drug-eluting stent
- Percutaneous coronary intervention